Litcius/Paper detail

783TiP Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS)

Alexander I. Spira, Ranee Mehra, Charlene Mantia, Hani M. Babiker, Mitesh J. Borad, Andrés Cervantes, Elena Garralda, Amit Mahipal, L. Paz-Ares, Christos Hatzis, A. Liu, Andreas Raue, Jinping Gan, Francisco Adrian, L. Manenti, A.B. El-Khoueiry

2022Annals of Oncology5 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAgonistCancer researchMonoclonal antibodyAntibodyCancerOncologyInternal medicinePharmacologyReceptorImmunologyMonoclonal and Polyclonal Antibodies ResearchCAR-T cell therapy researchCell Adhesion Molecules Research
783TiP Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS) | Litcius